Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyperprolactinaemia.

V K B Prabhakar1, J R E Davis

  • 1Department of Endocrinology, Manchester Royal Infirmary, Manchester M13 9WL, UK.

Best Practice & Research. Clinical Obstetrics & Gynaecology
|September 25, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Communication with young people in paediatric and adult endocrine consultations: an intervention development and feasibility study.

BMC endocrine disorders·2017
Same author

Phaeochromocytoma and Acromegaly: a unifying diagnosis.

Endocrinology, diabetes & metabolism case reports·2014
Same author

Wnt signalling in pituitary development and tumorigenesis.

Endocrine-related cancer·2013
Same author

Npas4 is activated by melatonin, and drives the clock gene Cry1 in the ovine pars tuberalis.

Molecular endocrinology (Baltimore, Md.)·2013
Same author

The prolactin gene: a paradigm of tissue-specific gene regulation with complex temporal transcription dynamics.

Journal of neuroendocrinology·2012
Same author

Third resection of pheochromocytoma aided by preoperative ¹²³I-MIBG scintigraphy and intraoperative gamma probe measurements.

Nuklearmedizin. Nuclear medicine·2011
Same journal

A risk-based classification of late-onset fetal growth disorders according to intrapartum fetal compromise.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

The Cardiac-Fetal-Placental Unit: links between umbilical venous flow and maternal hemodynamics in fetal growth restriction.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Psychosocial interventions for women who are pregnant following a previous reproductive loss: A scoping review.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Controversies in fetal therapy.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Alloimmunisation in pregnancy: current management and future perspectives.

Best practice & research. Clinical obstetrics & gynaecology·2026
Same journal

Consensus in prenatal management of Hemolytic disease of the fetus and newborn.

Best practice & research. Clinical obstetrics & gynaecology·2026
See all related articles

Hyperprolactinaemia, often causing reproductive issues, requires excluding other conditions before diagnosing pituitary tumors. Dopamine agonists effectively treat prolactinomas, shrinking tumors and restoring function.

Area of Science:

  • Endocrinology
  • Reproductive Medicine
  • Neuro-oncology

Background:

  • Hyperprolactinaemia is a common endocrine disorder linked to reproductive dysfunction.
  • Differential diagnosis is crucial, excluding pregnancy, medications, hypothyroidism, and PCOS before suspecting pituitary tumors.
  • Prolactinomas are most prevalent in women aged 20-40.

Purpose of the Study:

  • To review the diagnosis and management of prolactin-secreting pituitary tumors (prolactinomas).
  • To highlight the role of dopamine agonists as the primary treatment modality.
  • To discuss considerations for pregnancy and long-term management.

Main Methods:

  • Literature review of diagnostic criteria and treatment outcomes for prolactinomas.
  • Analysis of clinical presentations, including galactorrhea, gonadal dysfunction, and mass effects.

Related Experiment Videos

  • Evaluation of medical therapy (dopamine agonists), surgical, and radiotherapeutic options.

    • Main Results:

    • Dopamine agonists are highly effective in achieving tumor shrinkage and restoring gonadal function in most prolactinoma cases.
    • Medical therapy withdrawal can be considered in select patients under close monitoring.
    • Surgery and radiotherapy have limited roles in current prolactinoma management.

    Conclusions:

    • Dopamine agonist therapy is the cornerstone for managing both micro- and macroprolactinomas.
    • Careful planning and monitoring are essential for pregnancies in women with prolactinomas.
    • Further research into long-term outcomes and novel therapeutic strategies is warranted.